Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

MedicalXpress | juil. 02, 2026

For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with more meaningful reductions in hemoglobin A1C (HbA1c) levels than semaglutide, according to a study published online June 30 in the Annals of Internal Medicine.